Business
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a bioph
About this update from Cullinan Therapeutics, Inc.
[{"type":"image","alt":"Cullinan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cullinan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuI0MWklffj9jltO0FlcBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05","width":300,"height":157}},"lazy":false},{"type":"text","content":"Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025","length":163,"tagName":"p"},{"type":"text","content":"CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025","length":127,"tagName":"p"},{"type":"text","content":"Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting","length":93,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first quarter ended March 31, 2025.","length":332,"tagName":"p"},{"type":"text","content":"“As a leader in T cell engager development for autoimmune diseases, we continue to rapidly advance our global clinical development of CLN-978 in several autoimmune diseases and across multiple geographies. With an extensive global network of clinical investigators, CLN-978 is now in active clinical development in systemic lupus erythematosus (SLE), rheumatoid arthritis and Sjögren’s disease and we expect to deliver initial clinical data in SLE by the end of the year,” said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics.","length":540,"tagName":"p"},{"type":"text","content":"“In parallel, we continue to advance and refine our oncology programs. We recently announced that the pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib met the primary endpoint of overall response rate. Together with our partner Taiho, we will share the results in an oral pr...